Weekender: A pharma merger's impact ripples across West Virginia as Viatris plant closes

Signup | Forward Weekender July​ 31,​ 2021 | A roundup of this week's most read stories

TRENDLINE The Ongoing Developments in the COVID-19 Vaccine In this Trendline, discover key lessons learned and what hurdles still remain in the race to overcome COVID-19: Access now.   A pharma merger's impact ripples across West Virginia as Viatris plant closes One of the country's oldest and largest drug manufacturing plants will shut down Saturday, a casualty of the 2019 merger between Mylan and Pfizer's Upjohn unit. The impact will be felt by a West Virginia city for years to come. Bristol Myers withdraws Opdivo in liver cancer as fallout from FDA meeting continues With the decision by Bristol Myers, each of the two accelerated cancer drug approvals an FDA advisory panel voted to overturn in April have now been voluntary withdrawals. Pfizer, responding to criticism, presses case for COVID-19 booster shots During an earnings call Wednesday, a preprint paper was released showing a waning effect for the company's vaccine over time, one of a few data points Pfizer executives used to support the need for a booster shot.   Sponsored Content by Health Union Social health: The future of healthcare marketing Approximately 79% of patients look to connect through social media to find answers to their health questions. A startup raises $117M to deliver gene therapies in a new way Flagship Pioneering, the biotech incubator that created Moderna, is helping fund Ring Therapeutics, a startup hoping to disrupt gene therapy development through the use of a different viral vector. Regeneron, AstraZeneca team up on targeted drugs for obesity After screening 650,000 people, Regeneron unearthed a mutation associated with lower weight. AstraZeneca aims to help the biotech make a drug based on its findings.   In a first, FDA approves an 'interchangeable' biosimilar for diabetes An injectable insulin from Viatris has become the first-ever biosimilar product that can be directly substituted for a marketed biologic, a long-awaited decision that could put pricing pressure on other diabetes drugs.  Featured Resources FROM: Regulatory Affairs Professionals Society Flexible Learning. Lasting Impact. Advance your career: earn a certificate in pharmaceutical regulatory affairs from RAPS Online University Master the fundamentals: order the just-published Fundamentals of International Regulatory Affairs, Fifth Edition Stretch yourself: earn a dual certificate in regulatory affairs for pharmaceuticals and medical devices from RAPS Online University From Our Library Webinar - on demand The Shifting Data Frontier in Life Sciences Snowflake Playbook Transforming the Clinical Trial Experience with Patient Centricity Datacubed Health Trendline The state of biosimilars in 2021 View all resources Best of What We're Reading The Washington Post ‘The war has changed’: Internal CDC document urges new messaging, warns delta infections likely more severe Chemical & Engineering News Biomanufacturing draws hundreds of millions in investments Bloomberg Boston's Biotechs Pull Out All the Stops in Hiring Boom 'On Steroids' The Wall Street Journal Israel to Offer Pfizer Booster Shots to Elderly as Delta Cases Rise Endpoints News In CureVac's failure, a possible verdict on the past (and future) of mRNA vaccines Nature How the coronavirus infects cells — and why Delta is so dangerous Suggest a story we should read Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Daily Dive with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to BioPharma Dive: Daily Dive. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc. 1255​ 23rd Street NW, Suite 550, Washington,​ DC 20037. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip